scPharmaceuticals (SCPH)
(Real Time Quote from BATS)
$4.53 USD
-0.08 (-1.74%)
Updated Apr 24, 2024 02:44 PM ET
4-Sell of 5 4
F Value F Growth D Momentum F VGM
Income Statements
Fiscal Year end for scPharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 14 | 0 | 0 | 0 | 0 |
Cost Of Goods | 4 | 0 | 0 | 0 | 0 |
Gross Profit | 10 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 65 | 36 | 26 | 30 | 33 |
Income After Depreciation & Amortization | -55 | -36 | -26 | -30 | -33 |
Non-Operating Income | 9 | 3 | 0 | 0 | 2 |
Interest Expense | 8 | 3 | 3 | 3 | 2 |
Pretax Income | -55 | -37 | -28 | -32 | -33 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -55 | -37 | -28 | -32 | -33 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -55 | -37 | -28 | -32 | -33 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -55 | -36 | -25 | -30 | -33 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -55 | -36 | -26 | -30 | -33 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.51 | 28.36 | 27.35 | 24.57 | 18.60 |
Diluted EPS Before Non-Recurring Items | -1.42 | -1.30 | -1.02 | -1.31 | -1.77 |
Diluted Net EPS (GAAP) | -1.42 | -1.30 | -1.02 | -1.31 | -1.77 |
Fiscal Year end for scPharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 6.10 | 3.80 | 1.64 | 2.06 |
Cost Of Goods | NA | 1.77 | 1.08 | 0.35 | 0.61 |
Gross Profit | NA | 4.32 | 2.72 | 1.28 | 1.46 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 19.58 | 17.56 | 15.03 | 13.02 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -15.26 | -14.84 | -13.75 | -11.56 |
Non-Operating Income | NA | 3.54 | 1.27 | 1.60 | 2.31 |
Interest Expense | NA | 2.09 | 2.06 | 2.01 | 1.96 |
Pretax Income | NA | -13.81 | -15.63 | -14.15 | -11.21 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -13.81 | -15.63 | -14.15 | -11.21 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -13.81 | -15.63 | -14.15 | -11.21 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 38.79 | 38.76 | 38.69 | 37.80 |
Diluted EPS Before Non-Recurring Items | NA | -0.35 | -0.41 | -0.36 | -0.30 |
Diluted Net EPS (GAAP) | NA | -0.35 | -0.41 | -0.36 | -0.30 |